[go: up one dir, main page]

WO2017019974A1 - Endoprothèse urétrale transformable - Google Patents

Endoprothèse urétrale transformable Download PDF

Info

Publication number
WO2017019974A1
WO2017019974A1 PCT/US2016/044780 US2016044780W WO2017019974A1 WO 2017019974 A1 WO2017019974 A1 WO 2017019974A1 US 2016044780 W US2016044780 W US 2016044780W WO 2017019974 A1 WO2017019974 A1 WO 2017019974A1
Authority
WO
WIPO (PCT)
Prior art keywords
transformable
stent
ureteral stent
orientation
bore
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2016/044780
Other languages
English (en)
Inventor
Lance Michael Black
Saranya KARTHIKEYAN
Kamil MAKHNEJIA
Katie MERRITT
Vashina SHUKLA
Raymond PAK
Jaime Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Renastent LLC
Original Assignee
Renastent LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renastent LLC filed Critical Renastent LLC
Publication of WO2017019974A1 publication Critical patent/WO2017019974A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
    • A61M27/002—Implant devices for drainage of body fluids from one part of the body to another
    • A61M27/008—Implant devices for drainage of body fluids from one part of the body to another pre-shaped, for use in the urethral or ureteral tract
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2002/048—Ureters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
    • A61F2230/0028—Shapes in the form of latin or greek characters
    • A61F2230/0045—Omega-shaped
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
    • A61F2230/0028—Shapes in the form of latin or greek characters
    • A61F2230/0052—T-shaped
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0063—Three-dimensional shapes
    • A61F2230/0095—Saddle-shaped

Definitions

  • This disclosure relates to a medical device, and more particularly to a ureteral stent.
  • Nephrolithiasis is a medical condition better known as kidney stones. This obstruction in the ureter causes patients to experience varied degrees of pain as the stones and stone fragments pass through as peristalsis attempts to move the stones out of the body. Patients can also experience hematuria, nausea, vomiting, dysuria, and urgency. Kidney stone removal is achieved via ureteroscopy or ureteroscopy with lithotripsy, depending on the size of the stones. However, both of these procedures can be damaging to the ureter, resulting in ureteral strictures that may limit urine flow, ultimately causing hydronephrosis. Left untreated, hydronephrosis can result in permanent kidney damage. As such, ureteral stents are placed in the ureter after kidney stone removal, in order to facilitate urine flow as well as the passage of any remaining stones, thereby limiting development of
  • transformable ureteral stents that purposefully adapt to a dynamic ureteral environment.
  • a transformable stent may include an elongated body comprising a proximal end, a distal end, a longitudinal axis, an outer surface, and an inner surface.
  • the inner surface defines a transformable bore that may extend along the longitudinal axis from the proximal end to the distal end.
  • the transformable bore may include a default orientation and a second orientation.
  • the default orientation may include an open bore defining a longitudinally open channel.
  • the second orientation may include a closed bore defining a longitudinally closed channel.
  • the transformable bore may be moveable from the default orientation to the second orientation upon radial compression forces being applied to the outer surface.
  • a transformable stent may include at least two fins projecting radially away from the outer surface of the body.
  • FIG. 1 is a dimetric view of an example "wishbone”-style transformable stent in accordance with the present disclosure, wherein the image on the left represents the uncompressed status of the stent and the image on the right represents the compressed state;
  • FIG. 2 is a front-view of an another example "wishbone”-style transformable stent in accordance with the present disclosure;
  • FIG. 3 is a front-view of a another example "wishbone"-style transformable stent in accordance with the present disclosure
  • FIG. 4 is a dimetric view of an example "omega"-style transformable stent in accordance with the present disclosure, wherein the image on the left represents the uncompressed status of the stent and the image on the right represents the compressed state;
  • FIG. 5 is a dimetric view of an example "hinge"-style transformable stent in accordance with the present disclosure, wherein the image on the left represents the uncompressed status of the stent and the image on the right represents the compressed state;
  • FIG. 6 is a dimetric view of an example "spline"-style transformable stent in accordance with the present disclosure, wherein the image on the left represents the uncompressed status of the stent and the image on the right represents the compressed state;
  • FIG. 7 is a dimetric view of an example "arrow"-st le transformable stent in accordance with the present disclosure, wherein the image on the left represents the uncompressed status of the stent and the image on the right represents the compressed state.
  • FIG. 1 shows an example of a transformable stent 100 in accordance with the present disclosure having a "wishbone"-style design.
  • the transformable stent 100 can include an elongated body 101 comprising a proximal end 102, a distal end 104, a longitudinal axis 106, an outer surface 108, and an inner surface 110.
  • the inner surface 110 can define a transformable bore 1 11 that extends along the longitudinal axis 106 from the proximal end 102 to the distal end 104.
  • the distance between the distal end 102 and the proximal end 104 can be, for example, 20-30cm.
  • the transformable stent 100 itself can have a mid-fin diameter between about 4.8-8Fr.
  • the transformable stent 100 can include at least two fins 1 12 projecting radially away from the outer surface 108 of the body which allow for the transformable stent 100 to seat itself into the natural inner geometry of an undilated ureter.
  • An undilated ureter exhibits fingerlings and crevices, therefore the fins 112 of the transformable stent 100 can fit into these natural crevices.
  • the transformable bore 1 11 of the transformable stent 100 can be movable from a default orientation 1 13 A to a predictable second orientation 113B upon radial compression forces being applied to the outer surface 108.
  • the transformable stent 100 includes fins 112
  • the fins 112 can help stabilize the transformable bore 11 1 and facilitate the ability to direct the shape of the transformable bore 11 1 from the default orientation 1 13 A into the second orientation 113B.
  • the default orientation 1 13 A can comprise an open bore defining a longitudinally open channel and the second orientation 1 13B can comprise a closed bore defining a longitudinally closed channel, both which allow for urine to flow from the kidney to the bladder.
  • the radial compression forces can be provided by the normal and pathologic ureteral as well as proximal tissue physiology.
  • the default orientation 1 13A and the second orientation 113B support urine flow not only through the transformable bore 1 11 but also around the outer surface 108 of the body 101. As shown in FIGs. 1-7, when the
  • transformable bore 111 is the second orientation 113B, in certain embodiments the transformable stent 100 is not contiguously closed but rather is non-contiguously closed. In certain embodiments, when the transformable bore 111 is the second orientation 113B, the transformable stent 100 is contiguously closed.
  • the transformable bore 111 of the transformable stent 100 can be movable from a default orientation 113A to a predictable third orientation (not shown) upon radial compression forces being applied to the outer surface 108.
  • the third orientation can comprise, for example, a partially closed bore defining a longitudinally partially closed channel. Similar to the first and second orientation, the third orientation allows for urine to flow from the kidney to the bladder.
  • the inner surface 110 of body 101 has a diameter which can be reduced upon the transformable bore 111 moving from the default orientation 113 A to the second orientation 113B.
  • the diameter is reducible up to the point above where urine flow through the transformable bore 111 would be compromised.
  • the diameter could be reduced to that of a pediatric stent (approximately 3Fr), which could still support drainage comparable to that of a 4.7Fr stent.
  • the diameter can be reduced by about 40% upon the transformable bore 111 moving from the default orientation 113A to the second orientation 113B.
  • the reduced internal bore diameter can be about lmm.
  • the transformable stent 100 can be formed from a flexible material such as silicon, rubber, or plastic.
  • the fins 112 and body 101 comprise a flexible material that, based on the Shore hardness scale, is medium soft to medium hard, or medium hard to hard.
  • the fins 112 and body 101 can have a durometer between about 40-70 A or about 85 -90 A, or more, for example 90-100A.
  • Durometer ranges include 30-100 A, 40-90A, 50-85 A, 70-100A, and 80-95 A.
  • the fins 112 comprise a flexible material that is soft to medium soft and the body 101 comprises a flexible material that is medium hard to hard based on the Shore hardness scale.
  • the fins 112 can have a durometer between about 15-40A and the body 101 can have a durometer between about 80-90 A.
  • the durometers described above allow for the stent 100 to be strong enough to avoid collapsing from the ureteral forces imparted on the stent 100 while being soft enough to prevent large amounts of irritation of the ureteral tissue. This results in greater comfort for the patient while allowing the transformable stent 100 to function as it is intended. It also allows for the ureterovesical junction (UVJ) present between the ureter and bladder to continue functioning normally.
  • the transformable stent 100 can be deformed and flattened though the ureteral opening in the bladder allowing the valves to close when voiding the bladder, thus decreasing reflux into the ureter and kidney.
  • the durometers of the transformable stent 100 can also help prevent adverse tissue effects in the renal pelvis of the kidney and bladder from currently marketed ureteral stent anchors.
  • a softer set of anchors still function to prevent implant migration but also reduce patient discomfort from anchors protruding into surrounding tissues.
  • FIG. 2 shows another example of a transformable stent 200 in accordance with the present disclosure, the transformable stent 200 having a "wishbone"-style and the dimensions identified below which would allow that the transformable stent 200 to be capable fitting through a standard cystoscope or ureteroscope.
  • the transformable stent 200 is similar to the transformable stent 100 having depicted in FIG. 1, like references symbols are used to indicate like elements. The difference between the transformable stent 200 and the transformable stent 100 are disclosed below.
  • the transformable stent 200 is comprised of three fins 212 that are aligned every 120 degrees.
  • Each of the fins 212 can include a rounded tip 220 having a diameter that ranges from, for example, about .001 to .011 inches.
  • the distance from the tips 220 to the longitudinal axis 206 can range from, for example, about .038 to .043 inches.
  • each of the fins 212 can have a first straight side 235 and a second straight side 240 which can comprise, for example, substantially straight edges.
  • Each of the first straight side 235 and the second straight side 240 of each of the fins 112 can be the same or different.
  • the transformable stent 200 can include as part of the at least two fins 212, a top fin 245 and two bottom fins 250.
  • the first straight side 235 and second straight side 240 of top fin 245 can have a length that ranges from, for example, about .011 to .021 inches.
  • the bottom fins 250 can have a first straight side 235 and a second straight side 240 of different lengths.
  • the length of first straight side 235 can range from, for example, about .015 to .025 inches
  • the length of the second straight side 240 can range from, for example, about .011 to .021 inches.
  • the inner surface 210 of the body 201 can have a diameter that ranges from, for example, about .019 to .029 inches.
  • the outer surface 208 of the body 201 can have a diameter that ranges from, for example, about .031 to .041 inches.
  • the transformable stent 200 can also has fillets 225 on edges that range from, for example, about .001 to .011 inches in radius. Accordingly, the transformable stent 200 can fit within roughly a 2mm diameter (.079 inch) circle 260.
  • FIG. 3 shows another example of a transformable stent 300 in accordance with the present disclosure, the transformable stent 300 having a "wishbone"-style and the dimensions identified below which would allow that the transformable stent to be capable of fitting through a standard cystoscope.
  • the transformable stent 300 is similar to the transformable stent 200 having depicted in FIG. 2, like references symbols are used to indicate like elements. The difference between the transformable stent 300 and the transformable stent 200 are disclosed below.
  • Each of the fins 312 can have a rounded tip 320 having a diameter that ranges from, for example, about .007 to .017 inches.
  • the distance from the tips 220 to the longitudinal axis 306 can range from, for example, about .036 to .042 inches.
  • the inner surface 310 can have a diameter that ranges from, for example, about .025 to .035 inches.
  • the outer surface 308 can have a diameter that ranges from, for example, about .048 to.058 inches.
  • the transformable stent 300 can also have fillets on edges 325 that range from, for example, about .005 to .017 inches in radius.
  • the transformable stent 300 can include as part of the at least two fins 312, a top fin 345 and two bottom fins 350, however different from transformable stent 200, the top fin 340 does not have substantially straight edges and bottom fins 350 only has a first straight side 335.
  • the first straight side of the bottom fin can have a length that ranges from, for example, about .004 to .014 inches. Accordingly, the transformable stent 300 can fit within roughly a 2mm diameter (.079 inch) circle 360.
  • FIG. 4 shows an example of a transformable stent 400 in accordance with the present disclosure, the transformable stent 400 having an "omega"-style design.
  • the transformable stent 400 is similar to the transformable stent 100 having the "wishbone"- style depicted in FIG. 1, except the transformable stent 400 includes two fins 412, like references symbols are used to indicate like elements.
  • the transformable stent 400 is radially compressed, the fins 412 rotate towards each other, thereby moving the orientation of the transformable bore 411 from a default position 413 A to a second position 413B.
  • the roundedness of the outer surface 408 allows the radial forces that act upon it to disperse across its surface, leading to a minimal level bore deformation.
  • FIG. 5 shows an example of a transformable stent 500 in accordance with the present disclosure, the transformable stent 500 having a "hinge"-style design.
  • the transformable stent 500 is similar to that of the transformable stent 400 having the "omega" -style design depicted in FIG. 4, like references symbols are used to indicate like elements. The difference between the transformable stent 500 and the transformable stent 400 are disclosed below.
  • the transformable stent 500 exhibits two main features. One being a series of split transformable bores 511 which are features of the two fins 512. When a radially compressive force acts upon the transformable stent 500, the fins 512 rotate about the junction 565 of the fins 512 towards each other, thereby moving the orientation of the transformable bores 511 from a default position 513 A to a second position 513B.
  • FIG. 6 shows an example of a transformable stent 600 in accordance with the present disclosure, the transformable stent 600 having a "spline"-style design.
  • the transformable stent 600 is similar to that of the "hinge"-style design depicted in FIG. 5, like references symbols are used to indicate like elements.
  • the difference between the transformable stent 600 and the transformable stent 500 are disclosed below.
  • the transformable stent 600 can have an elongated body 601 that is constructed to have a spline feature 670 arranged in an s-shape that extends from the proximal end 602 to the distal end 604.
  • a radially compressive forces deforms the transformable stent 600, the ends 672 and 674 of the spline curl upon themselves, forming a transformable bore 611 in a second orientation 613B.
  • an s-shape is not necessarily required by the mechanism of this transformable stent 600 where the ends 672 and 674 curl towards themselves for the appropriate function.
  • FIG. 7 shows an example of a transformable stent 700 in accordance with the present disclosure, the transformable stent 700 having an "arrow"-st le design.
  • the transformable stent 700 is similar to that of the "hinge"-style design depicted in FIG. 5, like references symbols are used to indicate like elements.
  • the difference between the transformable stent 700 and the transformable stent 500 are disclosed below.
  • the transformable stent 700 includes three fins 712 of which two are side fins 776 and one of which is a bottom fin 750.
  • the side fins 776 can be a perpendicular to the bottom fin 750 and all of the fins 712 meet at the same point 765.
  • the inner corners of the fins 712 feature two transformable bores 711. When radially compressed, the side fins
  • the transformable stents can have the traditional pigtail curls on the proximal and distal ends for helping to anchor the transformable stents.
  • the size and shape of these curls can be as needed and understood in the art.
  • the curls can have a lower-profile/size. This can be produced, for example, by a lower stent durometer that yields increased amount of friction.
  • Suitable coatings can be placed on the transformable stent.
  • the entirety of the stent is coated, effectively coating both the "inside” and “outside” of the stents in the closed bore orientation.
  • Beneficial outcomes of using the disclosed transformable stents include improved peristalsis of ureter which can be measured in animal models, improved vital signs in animal models, and improved urine flow in animal models.
  • the transformable stents provided herein can be utilized on patients by urologists after performing ureteroscopy or ureteroscopy with lithotripsy. After kidney stone removal, a patient's ureter is often inflamed from the procedure.
  • the device can be placed into a patient's ureter after the procedure, using, for example, a guidewire and stent positioner. Once in place, the device can be deployed by, for example, removing the sheath that encompasses it. Successful deployment can result in the transformable stent anchoring in the kidney and bladder so as to limit migration.
  • using a contiguously closed bore has the effect of restricting the transformable stent from transaxially coming off of the guidewire.
  • the transformable stent can be designed to have a relaxed configuration, in which the shape of the transformable bore is designed to be more closed allowing for the stent to 'hug' the guidewire more closely.
  • a relaxed configuration can include, for example, a decreased gap angle between two lever fins or a decreased gap distance with constant gap angle.
  • the transformable stent can be similar to Cook's
  • Resonance Metallic Ureteral Stent deployed via sleeve, where the sleeve/transformable stent combination is then deployed over a guidewire and the sleeve being removed after deployment.
  • a guidewire with increased thickness relative to a typical guidewire can be used.
  • Removal of the transformable stent is encouraged to be completed by an urologist; however, a patient can also remove the transformable stent on their own. Stent removal can be facilitated by, for example, a wire that is attached to the distal end of the transformable stent.
  • the transformable stent can be placed and removed slowly so as to not injure or cause significant discomfort to the patient.
  • Transformable stents in accordance with the present disclosure can be intended for single use applications. As such, prior to use, it is encouraged that the transformable stents be properly stored in their original packaging, in order to assure sterility before use.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Prostheses (AREA)

Abstract

L'invention concerne une endoprothèse transformable qui présente un corps allongé comportant une extrémité proximale, une extrémité distale, un axe longitudinal, une surface externe et une surface interne. La surface interne définit un alésage transformable s'étendant le long de l'axe longitudinal de l'extrémité proximale à l'extrémité distale. L'alésage transformable possède une orientation par défaut et une seconde orientation. L'orientation par défaut comprend un alésage ouvert délimitant un canal ouvert longitudinalement. La seconde orientation comprend un alésage fermé délimitant un canal fermé longitudinalement. L'endoprothèse transformable peut éventuellement comprendre au moins deux ailettes qui font saillie radialement à l'opposé de la surface externe du corps.
PCT/US2016/044780 2015-07-29 2016-07-29 Endoprothèse urétrale transformable Ceased WO2017019974A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562198452P 2015-07-29 2015-07-29
US62/198,452 2015-07-29

Publications (1)

Publication Number Publication Date
WO2017019974A1 true WO2017019974A1 (fr) 2017-02-02

Family

ID=57886907

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/044780 Ceased WO2017019974A1 (fr) 2015-07-29 2016-07-29 Endoprothèse urétrale transformable

Country Status (1)

Country Link
WO (1) WO2017019974A1 (fr)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018200051A1 (fr) 2017-04-25 2018-11-01 Strataca Systems Limited Dispositif de sonde et procédé d'induction d'une pression négative dans la vessie d'un patient
WO2018200643A1 (fr) 2017-04-25 2018-11-01 Strataca Systems Limited Cathéter et méthode d'induction d'une pression négative dans la vessie d'un patient
US10307564B2 (en) 2015-07-20 2019-06-04 Strataca Systems Limited Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion
US10426919B2 (en) 2015-07-20 2019-10-01 Strataca Systems Limited Systems and methods for inducing negative pressure in a portion of a urinary tract of a patient
US10512713B2 (en) 2015-07-20 2019-12-24 Strataca Systems Limited Method of removing excess fluid from a patient with hemodilution
WO2020110051A1 (fr) 2018-11-30 2020-06-04 Strataca Systems Limited Sondes urétérales, sondes vésicales, systèmes, kits et procédés pour induire une pression négative afin d'augmenter la fonction rénale
WO2020110049A1 (fr) 2018-11-30 2020-06-04 Strataca Systems Limited Endoprothèse ou cathéter urétéral revêtu et/ou imprégné et procédé
WO2020110046A1 (fr) 2018-11-30 2020-06-04 Strataca Systems Limited Cathéter urinaire percutané
US10765834B2 (en) 2015-07-20 2020-09-08 Strataca Systems Limited Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion
US10918827B2 (en) 2015-07-20 2021-02-16 Strataca Systems Limited Catheter device and method for inducing negative pressure in a patient's bladder
US10926062B2 (en) 2015-07-20 2021-02-23 Strataca Systems Limited Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion
US11040172B2 (en) 2015-07-20 2021-06-22 Strataca Systems Limited Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion
US11040180B2 (en) 2015-07-20 2021-06-22 Strataca Systems Limited Systems, kits and methods for inducing negative pressure to increase renal function
WO2021240266A1 (fr) 2020-05-28 2021-12-02 Strataca Systems Limited Procédé de traitement faisant intervenir une thérapie rénale à pression négative et médicament(s)
US11229771B2 (en) 2015-07-20 2022-01-25 Roivios Limited Percutaneous ureteral catheter
US11541205B2 (en) 2015-07-20 2023-01-03 Roivios Limited Coated urinary catheter or ureteral stent and method
US12059543B2 (en) 2017-08-25 2024-08-13 Roivios Limited Indwelling pump for facilitating removal of urine from the urinary tract
US12064567B2 (en) 2015-07-20 2024-08-20 Roivios Limited Percutaneous urinary catheter
US12472301B2 (en) 2021-08-13 2025-11-18 3Ive Labs, Llc Negative pressure therapy system and methods

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3938529A (en) * 1974-07-22 1976-02-17 Gibbons Robert P Indwelling ureteral catheter
US5662713A (en) * 1991-10-09 1997-09-02 Boston Scientific Corporation Medical stents for body lumens exhibiting peristaltic motion
US5989207A (en) * 1997-11-03 1999-11-23 Hughes; Boyd R. Double swirl stent
US20020183853A1 (en) * 1999-03-18 2002-12-05 Fossa Industries, Llc Radially expandable stents
US20030153970A1 (en) * 2002-02-14 2003-08-14 Rao Doreen S. System for maintaining body canal patency and method thereof
US20040143209A1 (en) * 2003-01-22 2004-07-22 Liu Clifford M. Ureteral stent configured for improved patient comfort and aftercare
US20080288082A1 (en) * 2007-05-14 2008-11-20 Travis Deal Open lumen stent
US20110230950A1 (en) * 2008-09-16 2011-09-22 Tracey Knapp Stent
US20150134073A1 (en) * 2013-11-12 2015-05-14 Gyrus Acmi, Inc. Ureteral stents with waveform interlayers and interstitching

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3938529A (en) * 1974-07-22 1976-02-17 Gibbons Robert P Indwelling ureteral catheter
US5662713A (en) * 1991-10-09 1997-09-02 Boston Scientific Corporation Medical stents for body lumens exhibiting peristaltic motion
US5989207A (en) * 1997-11-03 1999-11-23 Hughes; Boyd R. Double swirl stent
US20020183853A1 (en) * 1999-03-18 2002-12-05 Fossa Industries, Llc Radially expandable stents
US20030153970A1 (en) * 2002-02-14 2003-08-14 Rao Doreen S. System for maintaining body canal patency and method thereof
US20040143209A1 (en) * 2003-01-22 2004-07-22 Liu Clifford M. Ureteral stent configured for improved patient comfort and aftercare
US20080288082A1 (en) * 2007-05-14 2008-11-20 Travis Deal Open lumen stent
US20110230950A1 (en) * 2008-09-16 2011-09-22 Tracey Knapp Stent
US20150134073A1 (en) * 2013-11-12 2015-05-14 Gyrus Acmi, Inc. Ureteral stents with waveform interlayers and interstitching

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11896785B2 (en) 2015-07-20 2024-02-13 Roivios Limited Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion
US11040172B2 (en) 2015-07-20 2021-06-22 Strataca Systems Limited Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion
US12076225B2 (en) 2015-07-20 2024-09-03 Roivios Limited Ureteral catheters, bladder catheters, systems, kits and methods for inducing negative pressure to increase renal function
US12064567B2 (en) 2015-07-20 2024-08-20 Roivios Limited Percutaneous urinary catheter
US10307564B2 (en) 2015-07-20 2019-06-04 Strataca Systems Limited Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion
US10426919B2 (en) 2015-07-20 2019-10-01 Strataca Systems Limited Systems and methods for inducing negative pressure in a portion of a urinary tract of a patient
US10493232B2 (en) 2015-07-20 2019-12-03 Strataca Systems Limited Ureteral catheters, bladder catheters, systems, kits and methods for inducing negative pressure to increase renal function
US10512713B2 (en) 2015-07-20 2019-12-24 Strataca Systems Limited Method of removing excess fluid from a patient with hemodilution
US12023459B2 (en) 2015-07-20 2024-07-02 Roivios Limited Negative pressure therapy system
US10610664B2 (en) 2015-07-20 2020-04-07 Strataca Systems Limited Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion
US12364845B2 (en) 2015-07-20 2025-07-22 Roivios Limited Pump, system and methods of inducing negative pressure to increase renal perfusion
US11040180B2 (en) 2015-07-20 2021-06-22 Strataca Systems Limited Systems, kits and methods for inducing negative pressure to increase renal function
US12357793B2 (en) 2015-07-20 2025-07-15 Roivios Limited Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion
US10765834B2 (en) 2015-07-20 2020-09-08 Strataca Systems Limited Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion
US10799668B2 (en) 2015-07-20 2020-10-13 Strataca Systems Limited Ureteral catheters, bladder catheters, systems, kits and methods for inducing negative pressure to increase renal function
US11918754B2 (en) 2015-07-20 2024-03-05 Roivios Limited Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion
US10918827B2 (en) 2015-07-20 2021-02-16 Strataca Systems Limited Catheter device and method for inducing negative pressure in a patient's bladder
US11077284B2 (en) 2015-07-20 2021-08-03 Strataca Systems Limited Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion
US10926062B2 (en) 2015-07-20 2021-02-23 Strataca Systems Limited Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion
US12226594B2 (en) 2015-07-20 2025-02-18 Roivios Limited Percutaneous urinary catheter
US11904121B2 (en) 2015-07-20 2024-02-20 Roivios Limited Negative pressure therapy system
US12274832B2 (en) 2015-07-20 2025-04-15 Roivios Limited Percutaneous urinary catheter
US10918825B2 (en) 2015-07-20 2021-02-16 Strataca Systems Limited Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion
US11229771B2 (en) 2015-07-20 2022-01-25 Roivios Limited Percutaneous ureteral catheter
US11904113B2 (en) 2015-07-20 2024-02-20 Roivios Limited Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion
US11420014B2 (en) 2015-07-20 2022-08-23 Roivios Limited Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion
US11471583B2 (en) 2015-07-20 2022-10-18 Roivios Limited Method of removing excess fluid from a patient with hemodilution
US11541205B2 (en) 2015-07-20 2023-01-03 Roivios Limited Coated urinary catheter or ureteral stent and method
US11612714B2 (en) 2015-07-20 2023-03-28 Roivios Limited Systems and methods for inducing negative pressure in a portion of a urinary tract of a patient
US11752300B2 (en) 2015-07-20 2023-09-12 Roivios Limited Catheter device and method for inducing negative pressure in a patient's bladder
WO2018200051A1 (fr) 2017-04-25 2018-11-01 Strataca Systems Limited Dispositif de sonde et procédé d'induction d'une pression négative dans la vessie d'un patient
EP4008372A1 (fr) 2017-04-25 2022-06-08 Roivios Limited Sondes urétérales et vésicales et procédés d'induction d'une pression négative pour accroître la perfusion rénale
WO2018200052A1 (fr) 2017-04-25 2018-11-01 Strataca Systems Limited Sondes urétérales et vésicales et procédés d'induction d'une pression négative pour accroître la perfusion rénale
EP3615125A4 (fr) * 2017-04-25 2021-01-20 Strataca Systems Limited Systèmes, kits et procédés pour induire une pression négative pour augmenter la fonction rénale
CN110785201A (zh) * 2017-04-25 2020-02-11 斯特拉塔卡系统有限公司 用于产生负压以增强肾功能的系统、套件和方法
WO2018200050A1 (fr) * 2017-04-25 2018-11-01 Strataca Systems Limited Systèmes, kits et procédés pour induire une pression négative pour augmenter la fonction rénale
WO2018200643A1 (fr) 2017-04-25 2018-11-01 Strataca Systems Limited Cathéter et méthode d'induction d'une pression négative dans la vessie d'un patient
US12059543B2 (en) 2017-08-25 2024-08-13 Roivios Limited Indwelling pump for facilitating removal of urine from the urinary tract
WO2020110049A1 (fr) 2018-11-30 2020-06-04 Strataca Systems Limited Endoprothèse ou cathéter urétéral revêtu et/ou imprégné et procédé
WO2020110046A1 (fr) 2018-11-30 2020-06-04 Strataca Systems Limited Cathéter urinaire percutané
WO2020110051A1 (fr) 2018-11-30 2020-06-04 Strataca Systems Limited Sondes urétérales, sondes vésicales, systèmes, kits et procédés pour induire une pression négative afin d'augmenter la fonction rénale
WO2021240266A1 (fr) 2020-05-28 2021-12-02 Strataca Systems Limited Procédé de traitement faisant intervenir une thérapie rénale à pression négative et médicament(s)
US12472301B2 (en) 2021-08-13 2025-11-18 3Ive Labs, Llc Negative pressure therapy system and methods

Similar Documents

Publication Publication Date Title
WO2017019974A1 (fr) Endoprothèse urétrale transformable
CN111787871B (zh) 流量控制阀
US7507218B2 (en) Stent with flexible elements
CN106794334B (zh) 输尿管支架
US11344697B2 (en) Retention drainage catheter
JP5666102B2 (ja) 治療薬の標的組織への送達における逆流を減少させるカテーテル
US7470247B2 (en) Ureteral stent
CN1142759C (zh) 为小肠提供液体连通的导管
CN107596539B (zh) 一种扩张球囊导管
JP6772386B2 (ja) カテーテル管
CN103068435A (zh) 包括远侧部分稳定性构件的可修剪导管
US20160213881A9 (en) Retention drainage catheter
CN105188790A (zh) 抗迁移支架涂层
US20050240141A1 (en) Stent kidney curl improvements
CN105073173A (zh) 锚定神经阻滞导管
US12171676B2 (en) Magnetically deployable urinary stent
US20170028176A1 (en) Transluminal implant and methods and apparatus for loading, delivering, and deploying an implant
JP2005312898A (ja) 改良型ステント
JP6593968B2 (ja) オーバ・ザ・ニードル式カテーテル用のスリーブ
WO2017158069A1 (fr) Ensemble cathéter
JP7054211B2 (ja) 涙腺ドラッグ送給デバイス
JP6928498B2 (ja) 補助デバイス
US8517971B2 (en) Cannula implant device for use in salivary gland ducts
US10039631B2 (en) Implant device for use in salivary gland duct
WO2024189432A1 (fr) Dispositif intra-urétral

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16831425

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16831425

Country of ref document: EP

Kind code of ref document: A1